Secondary Acute Myeloid Leukemia — Trials

Secondary Acute Myeloid Leukemia — Trials · CancerIndex

Clinical trials

Registered studies

212 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 46
Recruiting: 21
Ph III recruiting: 0
Growth YoY: —
Industry share: 7%
Top sponsor: National Cancer Institute (NCI)
Termination share: 31.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (39)

clinicaltrialsPublishedShowing 1–14 of 14 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04128501	Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting	active not recruiting	Phase 2	100	M.D. Anderson Cancer CenterOTHER	1	Sep 14, 2026	clinicaltrials
NCT03953898	Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation	active not recruiting	Phase 2	14	National Cancer Institute (NCI)NIH	1	Sep 10, 2026